Charlene Lancaster, PhD | Mar 12, 2024 | 4 min read
Using a circuit-based system, scientists determined the ideal transcription factor levels to promote the successful reprogramming of fibroblasts into induced pluripotent stem cells.
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Pathios Therapeutics ("Pathios"), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery ("Sygnature"), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes.